Danny Rischin, MD, MBBS, FRACP, discusses an ongoing phase III trial for patients with metastatic cutaneous squamous cell carcinoma or recurrent disease after progressing on frontline chemotherapy.
Danny Rischin, MD, MBBS, FRACP, director, division of cancer medicine, and head, department of medical oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses an ongoing phase III trial for patients with metastatic cutaneous squamous cell carcinoma or recurrent disease after progressing on frontline chemotherapy.
These patients are usually treated with a platinum-Taxol and bevacizumab (Avastin), but there are very few options after that, Rischin says. Survival rates after progression have also been very poor.
Nivolumab Combinations Debated for a Patient With Metastatic Melanoma
August 28th 2024During a Case-Based Roundtable® event, Hussein A. Tawbi, MD, PhD, and participants considered nivolumab/ipilimumab and nivolumab/relatlimab as options for a patient with metastatic melanoma in the first article of a 2-part series.
Read More